CEO Jonathan Drachman is presenting at the HC Wainwright Global Investment Conference...investor.neoleukin.com/news-releases/…

Pleased to announce that Bill Arthur, Ph.D., has joined Neoleukin as VP and Head of Research. investor.neoleukin.com/news-releases/…

Oral Presentation at @IDWeek2021 of Data Demonstrating NL-CVX-1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern... investor.neoleukin.com/news-releases/…

Neoleukin will present at the upcoming Stifel and Piper Sandler Virtual Healthcare Conferences. investor.neoleukin.com/news-releases/…

Preclinical data on Neoleukin's #denovoprotein NL-201 at #sitc2021. Visit the SITC website or read more here:investor.neoleukin.com/news-releases/…

Neoleukin announces clinical trial collaboration and supply agreement with Merck ... investor.neoleukin.com/news-releases/…

Neoleukin joined leading healthcare and life science companies this morning for the Nasdaq opening bell ceremony to kick off day one of the J.P. Morgan conference.livestream.com/accounts/27896…

Coming up next week, Neoleukin will participate in Guggenheim Healthcare Talks 2022 Oncology Day with a presentation on Thursday. investor.neoleukin.com/news-releases/…

Neoleukin will conduct a 2021 Financial Results Conference Call & Webcast on March 1, 2022... more info here: investor.neoleukin.com/news-releases/…

Today Neoleukin announced 2021 year end financial results and corporate update. Visit our website for press release and earnings call webcast link: lnkd.in/gDgs2DrS

Neoleukin announces upcoming presentations @aacr annual meeting #aacr2022 investor.neoleukin.com/news-releases/…

Neoleukin is pleased to welcome @dcochener as our General Counsel. investor.neoleukin.com/news-releases/…

Preclinical data on Neoleukin's NL-201 - including antitumor activity in B-cell lymphoma and synergistic activity in combination - highlighted in multiple presentations AACR Annual Meeting... #AACR22 #denovoprotein investor.neoleukin.com/news-releases/…

The Neoleukin team - Justin Huard, Ryan Swanson and Jonathan Drachman - connecting at our NL-201 poster presentation during the AACR annual meeting #AACR22 #denovoprotein

Today Neoleukin announced First Quarter 2022 financial results and corporate update. Please visit our website for full press release: investor.neoleukin.com/news-releases/…

Pleased to announce treatment of first patient in the combination arm of our Phase 1 trial evaluating NL-201 with KEYTRUDA® investor.neoleukin.com/news-releases/…

Today Neoleukin Therapeutics announced third quarter 2022 financial results and corporate update. Please visit our website for full release: investor.neoleukin.com/news-releases/…

Neoleukin presents data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits, in an oral presentation at the American Society of Hematology (ASH) Annual Meeting. #ASH2022 investor.neoleukin.com/news-releases/…

Neoleukin provides strategic update and announces restructuring and leadership transition... investor.neoleukin.com/news-releases/…

The previously announced merger between Neoleukin Therapeutics and Neurogene Inc is now complete. Please follow Neurogene Inc. for news and updates. Learn more here: bwnews.pr/3v0ilVM